Dr Reddy’s Laboratories today said it has inked a pact with US-based biotechnology firm Amgen to market its three drugs used to treat heart diseases and cancer in India.
The Hyderabad-based firm said it has entered into a strategic collaboration with Amgen to market and distribute three Amgen medicines in India in oncology and cardiology, Dr Reddy’s Laboratories said in a statement.
Under the terms of the collaboration, Dr Reddy’s shall undertake a full range of regulatory and commercial services to seek approval and launch the three drugs — Kyprolis, Blincyto and Repatha — in India.
Dr Reddy’s stock was trading at Rs 4,286.45 on BSE, up 2.18 per cent.
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)